Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 April 2023
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2019
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2017
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Capecitabine for the treatment of advanced gastric cancer (TA191)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2010
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2009
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC